6978 — Immunotech Biopharm Income Statement
0.000.00%
Last trade - 00:00- HK$1.74bn
- HK$1.69bn
Annual income statement for Immunotech Biopharm, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 99.6 | 436 | 351 | 301 | 326 |
| Operating Profit | -99.6 | -436 | -351 | -301 | -326 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -109 | -439 | -355 | -321 | -335 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -109 | -439 | -355 | -321 | -335 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -109 | -439 | -354 | -318 | -335 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -109 | -439 | -354 | -318 | -335 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.212 | -0.905 | -0.691 | -0.616 | -0.651 |